To explore the efficacy and toxicity of spatially fractionated radiotherapy in the treatment of tumors.
Conditions: Radiotherapy-Induced Immune Priming
Eligibility Criteria
Inclusion Criteria
- Patients with a bulky solid tumor with a maximum diameter \>4 cm or a refractory solid tumor.
Exclusion Criteria
- Tumors involving hollow viscera that are considered to have a clinically significant risk of bleeding or perforation.
- Patients with impaired consciousness or who are unable to care for themselves.
Eligibility criteria are kept as the original English records from ClinicalTrials.gov; actual eligibility is determined by the research team's formal assessment and the informed consent form. Source: ClinicalTrials.gov, updated automatically every two weeks. Last synced: 2026年10月8日.